Genomic diagnostics and research firm MedGenome plans to ramp up its research in the single-cell and immuno-oncology spaces while continuing to make inroads in the clinical genomic testing market in India.
The company has next-generation sequencing laboratories in Bangalore, India; Foster City, California; and Singapore. MedGenome CEO Sam Santhosh said that the Bangalore lab is primarily a diagnostics lab, while its large research projects are run mainly from its Foster City laboratory.
Last year, the firm raised $30 million in a Series C financing round, which it has used in part to expand its Foster City lab and purchase new technology, most notably 10x Genomics’ Chromium system and Illumina’s NovaSeq instrument.
Santhosh said that the company plans to focus upcoming research in the immuno-oncology space, including using single-cell sequencing techniques to analyze the tumor microenvironment.